金吾财讯 | 石四药集团(02005)绩后股价震荡走低，截止发稿，跌7.83%，报3.18港元，成交额4278.95万港元。公司午间公告，截至2024年12月31日止年度，公司股权持有人应占溢利为10.61亿元（港币，下同），同比减少19.53%，每股基本盈利0.3582元。董事局建议派发末期股息每股0.095港元，上年同期派息0.1港元。期内，收益为57.73亿元，同比减少10.67%。主要由于非PVC软袋输液及安瓿注射液的收益下降。毛利为29.08亿元，同比减少19.65%。研发成本为2.66亿元，同比减少8.21%。毛利率50.4%，同比下降5.6个百分点。与去年相比，本年度的成药通过集中采购销售的收入比例较大而且存量静脉输液及安瓿注射液产品的平均售价有所下降，但同时也促成了销售及分销成本的降低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.